Table 2.

Median (IQR) Plasma Markers from RA Patients Pre- and Post-Drug Interventions

Biomarker	Abatacept (n=27)		Anti-TNF (n=33)		Methotrexate (n=11)
	Pre-treatment	Post-treatment	Pre-treatment	Post-treatment	Pre-treatment	Post-treatment
IL-17 family
IL-17F (pg/mL)	70 (42–273)	45‡ (28–185)	159 (51–560)	118* (35–362)	61 (32–117)	23† (4–56)
IL-17A (pg/mL)	0.54 (0.3–1.14)	0.63 (0.29–1.14)	0.92 (0.53–1.18)	0.75 (0.45–1.09)	0.31 (0.22–0.49)	0.28 (0.16–0.44)
IL-17 A/F (pg/mL)	1.2 (0.6–2)	1.1 (0.8–2.5)	1.3 (0.7–2.4)	1.1 (0.6–2.4)	2.4 (2.3–6.4)	2.2 (2–4.6)
Other biomarkers
CRP (ng/mL)	5786 (1228–14783)	3528 (1188–8258)	8381 (2407–26275)	3173† (1803–9535)	8493 (6128–17974)	5590 (1744–8824)
IL-1 beta (pg/mL)	0.5 (0.37–1.01)	0.61 (0.32–1.55)	0.56 (0.34–1.25)	0.52 (0.32–1.27)	0.32 (0.19–0.62)	0.25* (0.08–0.38)
IL-6 (pg/mL)	4.9 (1.5–12)	4.4 (1.8–7.4)	4.8 (2.5–15.5)	3.8* (2–7)	9.9 (6.7–12.9)	3.8† (1.7–9)
sTNF RII (pg/mL)	5.3 (4.3–9.1)	4.7† (4–7)	6.5 (5.3–9.4)	10* (6.1–80.6)	4.5 (3.1–4.7)	3.6 (3.5–4.5)

The log ratio of patients’ post- to pretreatment marker was different from 0 (the expected value if there were no effect) at the following significance levels:

^*0.01≤p<0.05;

^†0.001≤p<0.01;

^‡p<0.001